Evidence map›Paper›PMID 29654436›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2018

Public funding for medical research in relation to the burden of disease caused by cardiovascular diseases and neoplasms in Germany.

Manuel Krone, Vera Dufner, Martin Wagner, Götz Gelbrich, Georg Ertl, Peter U Heuschmann

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Manuel KroneInstitute of Clinical Epidemiology and Biometry, University of Würzburg, Josef-Schneider-Straße 2/D7, 97080, Würzburg, Germany. manuel.krone@uni-wuerzburg.de.ORCID http://orcid.org/0000-0002-1020-6454
Vera DufnerInstitute of Clinical Epidemiology and Biometry, University of Würzburg, Josef-Schneider-Straße 2/D7, 97080, Würzburg, Germany.
Martin WagnerInstitute of Clinical Epidemiology and Biometry, University of Würzburg, Josef-Schneider-Straße 2/D7, 97080, Würzburg, Germany.
Götz GelbrichInstitute of Clinical Epidemiology and Biometry, University of Würzburg, Josef-Schneider-Straße 2/D7, 97080, Würzburg, Germany.
Georg ErtlDepartment of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
Peter U HeuschmannInstitute of Clinical Epidemiology and Biometry, University of Würzburg, Josef-Schneider-Straße 2/D7, 97080, Würzburg, Germany.
University of Würzburg · DEComprehensive Cancer Center Mainfranken · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPublic funding for medical research in Germany is primarily provided by the German Research Foundation (DFG) and the Federal Ministry of Education and Research (BMBF). The aim of this study was to analyze the amount of national public funding for medical research on predominant causes of death in Germany, cardiovascular diseases and neoplasms, in relation to the burden of these diseases in Germany.

methodsThree evaluators categorized medical research projects funded by the DFG or BMBF between 2010 and 2012 into the categories "Diseases of the circulatory system" (with subgroups "Ischemic heart diseases", "Heart failure" and "Cerebrovascular diseases") and "Neoplasms". The total amount of public funding by the national agencies was analyzed in relation to the burden of disease for the respective disease condition.

resultsInformation on national public funding for medical research of 2091 million euros was available; of those, 246.8 million euros (11.8%) were categorized being spent for research on "Neoplasms", 118.4 million euros (5.7%) for research on "Diseases of the circulatory system". This results in 362.08 euros per case of death, 16.58 euros per year of life lost (YLL) and 16.04 euros per disability-adjusted life year (DALY) for "Neoplasms" and in 113.44 euros per case of death, 8.05 euros per YLL and 7.17 euros per DALY for "Diseases of the circulatory system".

conclusionsIn Germany, research on cardiovascular diseases receives a lower share of national public funding for medical research compared to oncological research. These results are comparable to other European countries.

Indexed as

Cost of IllnessBiomedical ResearchCardiovascular DiseasesFinancing, GovernmentGermanyHumansNeoplasmsBurden of diseaseCardiovascular researchPublic research funding

Identifiers

PMID29654436
OpenAlexW2796803223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.